These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 26351392

  • 1. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.
    Launay O, Abitbol V, Krivine A, Slama LB, Bourreille A, Dupas JL, Hébuterne X, Savoye G, Deplanque D, Bouhnik Y, Pelletier AL, Galtier F, Laharie D, Nachury M, Zerbib F, Allez M, Bommelaer G, Duclos B, Lucht F, Gougeon ML, Tartour E, Rozenberg F, Hanslik T, Beaugerie L, Carrat F, MICIVAX Study Group.
    J Crohns Colitis; 2015 Dec; 9(12):1096-107. PubMed ID: 26351392
    [Abstract] [Full Text] [Related]

  • 2. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
    Cullen G, Bader C, Korzenik JR, Sands BE.
    Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451
    [Abstract] [Full Text] [Related]

  • 3. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.
    Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T.
    J Crohns Colitis; 2014 Mar; 8(3):223-33. PubMed ID: 24011513
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy.
    Shirai S, Hara M, Sakata Y, Tsuruoka N, Yamamoto K, Shimoda R, Gomi Y, Yoshii H, Fujimoto K, Iwakiri R.
    Inflamm Bowel Dis; 2018 Apr 23; 24(5):1082-1091. PubMed ID: 29538682
    [Abstract] [Full Text] [Related]

  • 5. Immune response to influenza vaccine in children with inflammatory bowel disease.
    Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A.
    Am J Gastroenterol; 2009 Feb 23; 104(2):444-53. PubMed ID: 19174786
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial.
    deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, Kaplan GG, Seow CH, Wrobel I.
    Inflamm Bowel Dis; 2016 Mar 23; 22(3):638-47. PubMed ID: 26595551
    [Abstract] [Full Text] [Related]

  • 7. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
    Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN.
    Clin Gastroenterol Hepatol; 2007 Jul 23; 5(7):851-6. PubMed ID: 17544875
    [Abstract] [Full Text] [Related]

  • 8. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.
    Matsumoto H, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T.
    J Gastroenterol; 2015 Aug 23; 50(8):876-86. PubMed ID: 25672513
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease.
    deBruyn JC, Hilsden R, Fonseca K, Russell ML, Kaplan GG, Vanderkooi O, Wrobel I.
    Inflamm Bowel Dis; 2012 Jan 23; 18(1):25-33. PubMed ID: 21472826
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.
    Caldera F, Hillman L, Saha S, Wald A, Grimes I, Zhang Y, Sharpe AR, Reichelderfer M, Hayney MS.
    Inflamm Bowel Dis; 2020 Mar 04; 26(4):593-602. PubMed ID: 31504526
    [Abstract] [Full Text] [Related]

  • 11. [The efficiency of influenza vaccines in patients with inflammatory bowel disease on immunosuppressive therapy].
    Farkas K, Terhes G, Deák J, Bálint A, Nagy F, Szepes Z, Wittmann T, Molnár T.
    Orv Hetil; 2012 Nov 25; 153(47):1870-4. PubMed ID: 23160078
    [Abstract] [Full Text] [Related]

  • 12. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 25; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 25; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 14. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 15. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab.
    Berglund A, Willén L, Grödeberg L, Skattum L, Hagberg H, Pauksens K.
    Acta Oncol; 2014 Sep 27; 53(9):1212-20. PubMed ID: 24865118
    [Abstract] [Full Text] [Related]

  • 16. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP.
    Ann Rheum Dis; 2008 May 27; 67(5):713-6. PubMed ID: 17965123
    [Abstract] [Full Text] [Related]

  • 17. Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients.
    Orcurto A, Pascual M, Hoschler K, Aubert V, Meylan P, Manuel O.
    Transplantation; 2012 Sep 27; 94(6):630-6. PubMed ID: 22895612
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.
    Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, Zettl UK.
    CNS Neurosci Ther; 2019 Feb 27; 25(2):245-254. PubMed ID: 30044050
    [Abstract] [Full Text] [Related]

  • 19. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.
    Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ.
    Vaccine; 2010 May 21; 28(23):3929-35. PubMed ID: 20394719
    [Abstract] [Full Text] [Related]

  • 20. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.